Full Transcript Introduction and Speaker Background 0:00 Welcome back to the Bioregulator and Peptides Summit folks. 0:02 Our next speaker brings something 0:04 truly invaluable to this conversation real world clinical perspective. 0:09 Doctor Gus Vickrey is a board certified family physician 0:13 dedicated to helping his patients 0:14 achieve optimal health, not just the absence of disease. 0:18 We've had long chats at various events about this, and Doctor 0:22 Vickery has been leading the charge now for quite a while. 0:25 His work is very impressive. 0:27 He's been in the trenches integrating bio regulators and peptides 0:31 into his clinical practice, and what he's observed 0:34 firsthand with his patients adds a layer of grounding 0:36 that you simply cannot get from research papers alone. 0:40 Today, Doctor Vicary is going to share some of those clinical observations 0:44 what he's seeing, what's working, what's surprising him, and how these tools 0:48 are changing outcomes for the people sitting across from him every day. 0:51 Please join me in welcoming Doctor Gus Vickrey. 0:54 Welcome, Gus. 0:55 Thank you. 0:56 Natalie. 0:56 It's always an honor, privilege and every other good accolade 0:59 I could give to get to have a conversation with you. 1:01 Well, back at you, sir. And thank you for taking the time. 1:04 So as we set up in 1:07 the intro, we're going to dive in together. 1:10 I mean, your board certified family medicine, 1:12 but you've definitely really leaned into this whole idea 1:16 of longevity and optimization medicine with your patients. 1:20 Do you want to talk about what kind of led you there? 1:22 And then maybe a little bit 1:24 about how you found by regulators, and then we're just going to dive in 1:27 because we're obviously trying to keep these tight for our listeners. 1:31 And yes, there's a lot to talk about a long story. 1:36 Pretty short train and family medicine started a practice right out of residency. 1:41 And, you know, 1:42 the first ten years of my career was doctors still go to the hospital. 1:44 You still if your patient moves to the ICU, you're taking care of them. 1:47 You're taking emergency department call. Pleasure managing him in clinic. 1:50 So you learn a lot 1:51 because you see people in all these different contexts, including severe 1:54 illness, moderate illness, and then just chronic illness or healthy in the clinic. 1:58 And about five years in, you start feeling a little more comfortable 2:02 with what you're doing. 2:02 Up until then, you're just like wondering who 2:05 how on earth people are still coming to you. 2:06 You know, but the 2:10 you begin to be able to step back and just do some meta observation. 2:13 And what I observed was a population of people who were just not that healthy. 2:16 Right. And a lot of these are 30 year old 40 year olds. 2:19 And it didn't resonate with me that 40 year olds 2:22 were coming in each year for a physical and had four chronic diseases 2:25 that I was going to represent medicines for. 2:27 Now it can happen. 2:29 Things can happen to people independent of, you know, their specific agency, 2:33 their genetic diseases. There are all kinds of things. 2:35 Nonetheless, it just didn't make sense. 2:37 And of course, a lot of it was metabolic disease. 2:39 But then there was the whole quagmire of fibromyalgia and insomnia and migraines 2:44 and headaches that were that I was taught about medical school, but there were 2:49 a good bit of my schedule in clinic, and these people were miserable. 2:52 And you realize that the pharmaceutical toolbox is a powerful toolbox. 2:55 It can be quite helpful, but it's not obviously resolving disease. 2:59 It's not, you know, reducing the variables 3:03 that are influencing the symptom of these specific conditions. 3:07 So that was when I began to really step back and take a deeper look 3:11 at like what's really influencing chronic disease, 3:15 lack of well-being, accelerated aging, and the population of people 3:19 who are trusting me to be their doctor. 3:20 And of course, what you begin today into is a whole lot of common sense, 3:24 like nutrition and environment and stress and sleep and toxins. 3:29 And then as you begin to introduce that 3:31 and people take action, you see improvements. 3:33 It's amazing how the body just starts moving and healing and metabolic 3:36 diseases are reversing. 3:38 And a lot of that might have been like early 3:39 on ketogenic diet, you know, with exercise, which are great 3:42 for people who have prediabetes to more rapidly reverse insulin resistance. 3:46 But eventually you start to then look into the therapeutic toolbox as well, right? 3:51 Various molecules beyond just medications, 3:54 nutraceuticals, botanicals and the data. 3:57 And you begin introducing those. 3:58 And then I was introduced to peptides, probably about almost ten years
Why Terrain Medicine Led to Peptides 4:03 now, ten years ago, and began to work with immune peptides 4:07 in people with auto immune disease and gut peptides. 4:10 And of course the growth hormone secreted. 4:13 And, you know, 4:14 the whole thing is we've talked about many times, and what I saw was 4:17 a, you know, a pretty significant 4:19 and that could be measured both objectively and subjectively. 4:23 But you talk about this on your podcast all the time, but 4:26 not unless you've addressed terrain first. 4:29 Right? Right. 4:30 And so most of my work is actually programing terrain. 4:33 And then what happens when you program terrain is a lot of times 4:36 you can sit back and watch the body go to work, 4:38 and it turns out 4:39 you don't even need to use all these other tools because it'll just 4:42 go ahead and start fixing itself, which is really fun to watch. 4:45 But when people have been trained into disease, 4:48 there's usually a level of dysfunction that requires 4:51 more than just nudging the body back, just setting the train. 4:54 Typically, you got to bring in some stronger 4:56 pushes right to the system to get it to undo compensations 5:00 and retrain normal, healthy homeostatic function. 5:03 So that's where peptides, I think, became very powerful tools 5:07 that we could add on to terrain work 5:10 to get from point A to point B a lot faster than we used to get. 5:13 And it was you 5:14 that brought by a regulatory peptides my attention, because I presented 5:17 a case study of a lady, a diabetic case, and it was a great one 5:22 because it had peptides and hormones and nutrients and everything. 5:26 And the woman had a remarkable transformation. 5:29 I still present that case study because people don't believe it's true 5:32 what could happen. And you were the one that said after me. 5:34 What if you had thought about the pancreatic bio peptide? 5:37 I was like, what is that? 5:38 You know, and I was like, tell me long talk. 5:42 Yeah, tell me about it. 5:44 And I think, I wonder when that was. 5:46 We were both there was that four years ago 5:47 maybe that we sat together and not I think it's longer. 5:51 Yeah. We were in Kentucky. 5:52 We were at the Wild Health Summit. 5:54 Yes, it was the Wild Health Summit. 5:56 And we talked for a long time. 5:57 And I went home and you introduced me to Hal, and he sent me. 6:01 He sent me that little dense canvasing book on all the research. 6:05 Yeah. 6:05 And then you set me up with profound health and I started 6:08 programing bio regulatory peptide stacks for my patients. So. 6:12 And I've been doing that ever since. 6:13 And so we are gathered here today to talk about 6:18 your observations. 6:19 Before we jump in, though, 6:22 I'm curious to ask you 6:24 where are there cases or people where you're more cautious 6:27 with the by regulators with is there an instance where you feel that 6:32 maybe people need to exercise some caution because they're generally speaking, 6:36 they're considered to be pretty safe, right. 6:39 But and I'm bringing this up because I feel like it behooves us 6:43 to share with the audience that even something that is 6:47 technically a safe, even when we're talking about the natural 6:50 bio regulators that are technically classified 6:53 as nutritional supplements, there might be a population 6:56 or two of people who might want to exercise extra caution. 7:00 And I mean, even with nutrition, right, like you can 7:04 there are particular diets that wouldn't be good for a particular person, 7:06 even though they would be considered just classic nutrition. 7:09 So it is really important. 7:11 These are molecules that have a biological impact. 7:13 And anytime you introduce something that's going to shift biology, 7:17 you have to recognize that there are this is an exaggeration, but 7:20 like an infinite number 7:21 of downstream consequences that you can't account for, right? 7:24 Which is typically the story of a lot of conventional medicine, 7:28 but even, say, functional medicine, where we get really excited about something 7:32 and it can have these benefits, 7:34 and then we're pushing it in, and then you start to see later that you 7:37 created challenges in these other systems because you modulated this one system. 7:41 And so I have this deep respect for the infinite complexity 7:45 of the human system, and that what we know is far, 7:49 far, exponentially less than what we don't know. 7:51 And so when you go to modulate a system, you have to do it with and with deference, 7:56 with humility and recognizing everything could have a potential impact. 7:59 So one, people who are already exquisitely sensitive 8:03 to biological inputs, and I'm sure you've encountered 8:06 many of these, I have some of them under my care. 8:08 And we're talking even, you know, like a higher dose but not a high 8:12 dose of niacin will create detectable, 8:16 uncomfortable impacts for that particular person. 8:20 And I said, well, niacin a bad choice because a lot of people it's a bad choice 8:23 because, yeah, 8:23 I had a pretty uncomfortable experience with a lot of people that one. 8:27 But, you know, let's just say thiamin instead or something like, I mean, 8:31 and so these people are exquisitely sensitive to these inputs, 8:35 and you're often getting a micro dose, 8:38 almost everything that you put into their system, 8:40 it doesn't mean I would, 8:41 wouldn't use a bio regulatory peptide, but I would start with the lowest dose. 8:44 I could use probably one peptide and make sure that their system 8:48 tolerated it well. 8:49 And before I begin to escalate in those individuals cancer, I'm really care. 8:54 I cancer to me is you know we it's there's a lot of better understanding of cancer. 8:59 And I think that the research is great and I think there's a lot of merit 9:03 to complementary approaches to cancer with a deference 9:07 to the conventional treatments, if they are research based 9:11 and probably effective, 9:12 you don't want to interfere with what they're designed to do, 9:15 which a lot of complementary approaches could actually serve as a form 9:18 of interference to the conventional I think, wedding. 9:21 The two together intelligently is the best approach, but I don't. 9:25 If you were to ask me to, I think bio peptides 9:27 would potentially a cancer, I would say probably not. 9:29 How do you. 9:29 Not likely. 9:30 But at the same time, their mechanistic activity of increasing gene expression, 9:35 I would probably 9:37 avoid them while somebody is being treated for active cancer in their body. 9:41 But once they're in remission, then I would not 9:44 necessarily avoid it, but I might avoid the target tissue. 9:47 That was their cancer right. 9:49 Because if for a couple of reasons one is 9:52 we never know like if you go and tap the DNA in that area. 9:55 Do you unlock some things that you couldn't have anticipated. 9:58 Probably not would be my answer. 9:59 But you don't know the answer. 10:01 Two cancers tend to come back on colleges, ask a lot of questions 10:06 and you don't want to be sitting there talking to them on college. 10:08 Just saying, 10:08 why did you put them back on a pancreatic DNA modifier when I when 10:12 they were treated for pancreatic cancer? 10:14 I don't want to be in the position of answering those questions. 10:16 No, no that's uncomfortable. 10:18 And maybe pregnancy. 10:20 Yeah. Pregnancy I agree as well. 10:22 Yeah but I would yes I think that's a great one that yeah 10:25 I don't treat a lot of pregnant people. 10:27 No I know but I 10:29 but but just if, if we're going to but that kind of covers it so okay. 10:32 So now you mentioned the 10:34 you've had a lot of great success with the pancreatic bio regulators. 10:37 So maybe let's talk about that one. 10:39 Because you know these are interesting days. 10:42 Everybody every second person you talk to seems to be on a JLP 10:46 peptide protocol of some kind. 10:49 There is some evidence that it does. 10:51 Well, never mind evidence. 10:52 It gets the pancreas working a little harder. Yes. 10:55 And maybe a pancreas that's been a bit beaten up over the years 10:59 and may or may not remember how to do its job properly.
When to Use Caution with Bioregulators 11:02 So let's talk a little bit about where the pancreas 11:06 regulator has kind of surprised you at times. 11:09 Or maybe at the beginning. 11:10 And now it doesn't anymore. But yeah. 11:12 Yeah exactly. 11:13 And so in general use, I would look at it from the standpoint 11:16 of whether it's insulin resistance, beta cell dysfunction or even exocrine. 11:21 And I'm not aware of any specific data around 11:24 pancreatic exocrine function meaning digestive enzyme production. 11:28 But you know, when we do gut assessments, we commonly see, 11:31 especially in older individuals, very low pancreatic exocrine function. 11:34 And so that's one area that I'm like, well, 11:36 if that comes along for the ride, great. 11:37 You know, I can't say that I've been able to necessarily measure that. 11:42 But the specific use cases I can give you. 11:44 So I'm using protocols with the pancreatic peptide for people, 11:49 whether it's they need to improve insulin resistance 11:52 or they need to improve beta cell function. 11:54 Now, most insulin resistance will eventually have some component 11:58 of beta cell dysfunction as well. 11:59 So you could almost just say that's probably coming on for the ride, 12:02 even if you're still measuring high insulin, right in that individual. 12:05 But there's a a type of case that it's not uncommon. 12:10 It's not as common as insulin resistance where people will present 12:13 and they'll have a hemoglobin A1 of say, 5.8 pre-diabetic. 12:17 Right. So they have glucose volatility. 12:19 They'll have normal to borderline high fasting blood glucose. 12:23 All other markers of insulin resistance are normal including 12:26 a lipid particles triglycerides HDL small dense LDL. 12:29 There is not a pattern of resistance. 12:31 And they're often not overweight. 12:33 And they're they're fit. 12:34 Insulin levels will tend to be on the low side of normal or even low in sea. 12:39 Peptide levels will be on the low side of normalcy. 12:41 Peptide way of measuring endogenous insulin. 12:44 So with these people, some of the data suggests that and it makes perfect sense. 12:48 Low carbohydrate diets or ketogenic diets will prolong their beta cell function, 12:54 meaning it's less likely to devolve towards like a beta cell type, 12:59 you know, type of diabetes, where they may actually have to look at insulin 13:03 as an intervention because that's in these cases, going 13:06 after insulin resistance isn't going to do a lot for you. 13:08 It's purely can we improve 13:10 endogenous insulin production in response to the proper signal. 13:15 So in these, you know, so in these cases, you know that this person's 13:21 borderline high or high hemoglobin ANC is actually insufficient 13:26 pancreatic production of insulin, 13:27 likely when they're eating mills, even if they're eating lower carbohydrate, 13:31 they still might not tolerate much of a carbohydrate at all. 13:34 Or if they do, a high protein diet where a good bit of that 13:36 protein is being converted to glucose, it can still cause that. 13:39 Now these were at least five, I might have more, but at least five cases of people 13:43 I had followed for years with exactly the same metrics 13:47 and who didn't progress, but were also using like low carbohydrate, 13:51 avoiding sugar, getting movement after mills, 13:55 doing things to try and make sure that they put less stress on the pancreas. 13:59 The only intervention in each of these cases was to do a protocol that included 14:03 pineal, thymus, blood vessel and pancreas and pancreatic peptide. 14:06 And the dosing protocol at that time was 30 days right, 14:10 a 30 day straight push of taking each peptide together, 14:13 followed by ten days out of 30 for the next 6 to 12 months. 14:17 Right. So we were like, this is going to take a while. 14:19 We're not going to just see beta cells, you know, 14:22 signs of cell regeneration and a couple of months. 14:25 And it was interesting because what happened in every one of these cases, 14:29 which again, there are other things these people are doing 14:31 to potentially improve control. 14:34 But this was the only new intervention. 14:36 And what was a stable situation for years. 14:39 And in every one of these cases, see peptide levels normalized. 14:43 Now they didn't become like high, but they normalized on the low 14:46 end of the range as opposed to being low insulin levels 14:49 improved as whatever percentage of the range they were in. 14:52 And AMC is typically dropped from a 5.7 or 5.8 to a 5.2 or 5.3. 14:58 And so can I say, 15:00 can I absolutely say that that was the bigger peptide that didn't know? 15:03 I cannot not from a scientific do I strongly believe that influence 15:07 beta cell function? Yes I do. Yeah. 15:10 Yeah yeah. No that's that's pretty amazing. 15:12 It's interesting that you kept and so did you keep measuring along the way. 15:16 And did some people kind of you saw the improvements at six months 15:19 or did everybody pretty much take it was really 12 months. 15:22 And that's the same thing 15:23 with any other use cases we go into except for, well, not everyone. 15:27 But if we talk about kidney, it's the same deal. 15:30 It was a good year of, well, let's talk about kidneys. 15:34 But then we maintained right to. 15:35 So these people continued 15:37 every three months taking a ten day course of that bowel regulatory peptide. 15:41 They're still taking it right. Yeah. Today you know. 15:43 But but ten days every three months is no longer a massive commitment. 15:47 You're, you're into. Yeah. You're getting into. 15:50 So let's talk a little bit 15:52 I know you we've talked about you talked about pancreatic. 15:56 You've you talked a little bit about adrenal and kidney. 15:59 Like those are those three I mean not that there's not others. 16:02 And you know as time goes on there will be others. 16:04 But those three I think is where you said you've so far 16:07 observed the most notable shift. 16:11 And I think that's for good reasons. 16:13 You know, I don't manage a massive population of people anymore. 16:15 So at any given moment there's 200, 300 people. 16:18 So I'm not going to one, I'm not going to have a high volume 16:20 of any one particular thing. 16:21 The kidney, you know, issues beta cell insufficiency, adrenal underperformance. 16:27 You know, these are really common in our population. 16:29 So you're likely going to encounter them. 16:31 And they're also modifiable. 16:34 Every single one of those was modifiable 16:36 before by introduced by regulatory peptides. 16:38 We knew that these things could change. 16:39 Well I hadn't seen much with the beta cell function actually. 16:42 Be honest that one. 16:43 But the others that I have and we can measure, right. 16:47 We can we can clearly measure objective biomarkers 16:50 that index to the function of that particular tissue type. 16:53 So these are easier ones 16:55 where it's going to be harder to to actually measure cartilage. 16:59 Right. 16:59 Or muscle, you know, or even intestine.
Pancreatic Bioregulator Results 17:02 It's really hard to measure 17:03 like is there is a is there an improvement or not 17:06 in the intestinal environment from it. 17:07 But these we can measure. 17:09 So with kidney obviously kidney insufficiency or chronic kidney 17:12 disease is very common in our population. 17:14 There's a lot of different reasons for it. 17:16 And I think you've probably had people who are like integrative specialists 17:19 with kidney on your podcast to talk about protocols that you can. 17:23 Yeah. 17:23 And I have one coming up right after you actually. 17:26 Yes. Excellent. 17:27 And so yeah, everything that they're going to talk 17:29 about doing like from nitric oxide and glutathione and amino 17:32 acid availability, those are all absolutely critically important. 17:35 If you want a chance for your kidneys to at least not progress 17:38 into a deeper state of disease, 17:40 or if you'd like to see some reversal of that disease. 17:43 And with kidneys, there's so many variables that influence it. 17:46 And you're never, of course, going after just one and any kind of scenario. 17:50 So it's hard to say okay. 17:52 Was it the regulatory peptide or was it this. 17:54 But these were similar cases in the sense that we had addressed 17:57 a lot of those other things that, you know, 18:00 and maybe I'm going to learn more from your kidneys 18:02 specialist of things that we can do to help those cases. 18:04 And we introduced the same thing, 18:06 a protocol with pineal, thymus, blood vessel and kidney 18:09 and then monitored renal function metrics and system and see glomerular 18:13 glomerular filtration rate, urine microbiome and protein, things like that. 18:16 And each of those cases, 12 months out we saw measurable improvement 18:21 in kidney function. 18:22 And so some degree of reversal of the kidney and sufficiency. 18:26 And with the kidneys, if you can stabilize that at stage one. 18:29 Stage two. 18:30 And then if you can just yeah, 18:32 if you can just keep it there and it's not going to progress, 18:34 then you can go ahead and live another 18:35 50 years or 70 years or whatever with kidneys doing that. 18:38 So it's critically important. 18:40 And kidneys effect as you know, everything. Right. 18:43 So kidney impairment is like it affects, you know, 18:47 cardiovascular and blood pressure and mineral cortical balance 18:52 and detox like like it's a pretty vital organ. 18:56 Yeah. It's the forgotten organ back there. 18:59 Yeah, yeah. 19:00 And so and so kidney is also one like if I'm just doing more health 19:04 maintenance rotations of bio regs we might not do it every time. 19:07 But kidneys getting into the rotation on some kind of consistent basis. 19:11 Yeah. Yeah. 19:12 And then adrenal if you want me to if you want to ask questions 19:14 you can or I can jump over, you know. 19:16 Well I mean you know I think with kidney 19:19 you know, 19:19 definitely the doctor Robin Rose, who lives in Hawaii. 19:24 So there's two doctor Robin Rose's, 19:25 there's one who lives in Hawaii, one who lives in New York, 19:28 and the one who lives in Hawaii is a specialist. 19:31 And she would say that the lion's share of adults in the US 19:36 are walking around with undiagnosed, almost stage two, if not stage two CKD. 19:42 Yeah, I don't disagree. I think most people. 19:44 Yeah. 19:45 Stage one we see commonly in the data but it's it's not going to get reported. 19:48 It's not going to be discussed with exactly. 19:50 She's like it's accepted right. 19:52 The problem it's a little bit like tolerating to high blood 19:55 glucose or to high fasting insulin. 19:59 You're awfully close to the edge of that cliff. Yes. 20:02 And it's it doesn't take much to get you to push you over if you don't. 20:05 Course. Correct. 20:06 So I do think that I think and to your point 20:10 with the bio regulators, you don't have to wait until you have a problem to 20:15 bring them on board and do some, I call it maintenance work. 20:19 Touch them up. 20:19 Just touch them up. Just do a little touch up. 20:21 Yes, exactly. 20:23 Now with adrenals, 20:24 what has been your experience with the adrenal by a regulator? 20:27 Have you. 20:28 I've had really positive results with adrenal. 20:30 Now once again, we're we're addressing 20:33 everything that might be causing the cortisol signal to be dropping out. 20:37 You know, and so this is really common. 20:39 And the last time we got together and we went through metabolomics, 20:42 we spent a lot of time on sympathetic nervous system dominance. 20:45 And the more that and by the way, the deeper I keep going with metabolomics 20:49 and then pulling the metabolites and running my own AI modeling on it. 20:53 And like that, that pattern of sympathetic dominance is like, it's everybody, 20:57 right? 20:57 It's there and it's influencing everything else. 21:00 And it's not the only thing affecting adrenal function, but is one of the major 21:04 things that would cause through a negative feedback loop for your 21:08 your own adrenal glands to start producing less cortisol, amongst other things. 21:12 And so it's really common for me, for people, 21:15 whether they're chronically sick, and that's why they've come to me 21:18 or they're the high performer, Uber athletic, constantly 21:22 putting too much demand pressure on their system. 21:24 Either way, 21:25 I rarely see optimal cortisol signal and so must always a little suppressed. 21:30 It may not be abnormally low, but it's on that low side of the range. 21:33 It's not. 21:34 It's not following the typical pattern we expect. 21:36 And it's important right. 21:37 Like I mean cortisol signal is critically important. 21:40 Yes to a lot of people are on in stress responses have higher cortisol 21:44 and can that you know contribute to metabolic disease and immune. 21:48 Yeah absolutely. 21:49 But I think from the standpoint of over time 21:53 what we see more of is low cortisol or at least lower than optimal cortisol. 21:58 And so, you know, it's a very important signal that you need to address. 22:03 Right. 22:03 Because if you're working on cell membranes and mitochondria and detox 22:07 and clearing all this stuff, but you're not, you know, restoring 22:10 hormonal balance and autonomic nervous system balance to the extent that you can 22:14 then ultimately the that sea is going to become the same. 22:18 See, it was over a matter of time, right? 22:20 Yeah. 22:21 And so with adrenal commonly see it 22:24 obviously there are adaptogens that have some pretty good data 22:28 around their influence on cortisol signal and stress balance. 22:32 But they're typically working through a medic basis. 22:36 Right. 22:36 So they're often causing a little stress to induce that response. 22:40 That's not necessarily a bad thing, but there are cases 22:42 where you realize this person doesn't need any more, like signals of stress. 22:46 This is not the time. Yeah. 22:48 And so I have found and this is one of the only ones that I've done. 22:52 Well, I've done pineal solo. Right. 22:54 Like I'll put people on pulses 22:56 of pineal pineal just because of the evidence around, 23:00 you know, the pineal gland function, melatonin, telomere lengthening 23:05 I'm like that's a good peptide to to maybe your touch up 23:09 might be a really frequent touch up with that one. 23:12 I think you can make a pretty good case for that. 23:14 But the only other peptide that I would consistently use as a solo 23:18 agent would be the adrenal. And I've seen results 23:20 with just the adrenal, like just putting people on that. 23:23 It started because I would have people 23:25 that we put together stacks for everything else, 23:27 and they were already hitting 23:28 an overwhelm point and they were like, I don't think I can do these for peptides. 23:32 So I'd say, why don't we just do adrenal and add it in? 23:34 And we measured results like was we're measuring adrenal function over time 23:38 I've had and whether there is placebo or not, I cannot say I've had patients 23:42 who take the adrenal peptide and say, I can tell that I have more energy. 23:47 I feel better now. 23:49 Yeah, I know, but nonetheless, I'll take it, you know? 23:53 Yeah. 23:53 No, I mean, look, 23:54 even if they think that they feel better, that's it's a win, right? 23:57 It's part of feeling better. Yeah. 23:59 Anything that inspires confidence in their own mind
Kidney and Adrenal Support 24:01 that their body can restore health, will will absolutely influence 24:04 their overall result right from their efforts. 24:08 Reprograming help that confidence because the confidence ties into stress, right? 24:12 Like if you're thinking isn't going to work, I'm a hopeless case. 24:15 My body has failed me. 24:17 There's no hope for me. 24:18 But hey, I'll try anyway. 24:20 That's that's just a whole different environment 24:22 of central nervous system programing, threat versus safety versus. 24:26 Hey, you know what I've been saying for a long time, 24:28 but I do believe my body can heal. 24:29 And I'm really confident in this plan. 24:31 And I think this plan will work for me. 24:33 Huge difference in outcomes I believe. 24:35 And so with the adrenal, I've had people subjectively report improvements. 24:39 I don't know. Right? 24:40 I can't say one way or the other, but I'll take it. 24:42 But we've clearly measured improving cortisol. 24:44 And I'm not talking about monumental stuff. 24:46 I'm talking about somebody who's a basal cortisol level. 24:48 If it was a blood test as a fight, that's low, right? 24:51 Especially at 10:00 in the morning, that's cortisol. 24:54 And then three months later 24:56 it's a seven and a half, and then three months later it's a ten. 25:00 Right. 25:00 And then it might still take another 12 to 18 months before it's a 14 again. 25:05 But there's clearly this stepwise incremental improvement, 25:09 along with go outside 25:11 into nature and breathe and get more sleep and everything else you need to do. 25:15 But I believe that adrenal peptide is effective, I do. 25:19 Yeah, that's really interesting. 25:21 So do you ever pair adrenal with thyroid? 25:25 Yeah, because it's really common to have people with and with both right. 25:28 Yeah. 25:29 Yeah I would is the one where I, you know, I still believe that 25:33 it has the potential to normalize and balance that weight function. 25:36 I haven't measured a lot of outcomes. 25:38 And with my thyroid peptide. 25:40 And so obviously we're looking at for 23324 antibodies reverse T3. 25:45 And we've added in for people. 25:46 But I can't say that I've seen a clear cluster like I have with the others of 25:50 oh wow. Like that our weight is improving. 25:53 Let's win you off medication, things like that. 25:56 Yeah. It's interesting. 25:57 I mean, I've seen a couple of those cases in my membership community 26:00 where people were working with physicians or natural paths, and the thyroid 26:04 bio regular seemed to be the last piece of the puzzle 26:08 that needed to lock in for them to see real, real results. 26:12 But, you know, as you say, like it depends on your patient population as well. 26:16 Yes, but I'm still I'm still going to keep using it in people. 26:20 Sure. For sure. 26:21 So you've mentioned a few times how that the bio regulators don't 26:26 they're not going to over perform. 26:27 They're not your diva right. 26:29 They're not your yes. They're not the diva peptide. 26:31 They're the get in, get the work done and get out peptide. 26:34 And maybe speak to that a little bit about, 26:38 you know, how that inspires your work 26:40 and and maybe even your confidence in using them over time. 26:44 Yeah, I think it's really important because what we talked about earlier, 26:47 all these downstream consequences that we can't measure or account for, 26:51 things that we don't even know about yet, right, in terms of human complexity. 26:55 And so you again, have to have this like cautionary principle 26:59 when you begin to create new biological inputs into this complex system. 27:03 One knowing that you're unlikely to cause harm is really, really helpful. 27:07 You know, because that's not true of every tool we use. 27:10 Some of the peptides we use have clear potential adverse effect profiles 27:13 that you have to monitor for. 27:15 And and they're powerful signaling molecules that you're 27:18 using at higher doses to, to create a particular response 27:22 bio regulatory or you know there's very elegant there. 27:26 You know there are one. 27:26 They're reproducing something that's a natural process for the body. 27:30 And you look at their DNA interactions. 27:31 That has to do with like chromatin. 27:33 It's complicated, but it's not just simply I'm just turning these genes on. 27:37 Right. It's winding the helix. 27:40 That's exactly right. 27:41 It's it's potential, 27:43 the possibility that you could improve this genetic expression. 27:47 I improve the protein and enzyme environment of that particular cell line, 27:52 which might impact functionality, might meaning just because the enzymes produced 27:56 if it's not needed, it's not doesn't mean it's going to do anything for you. 27:59 Because the body is so intelligent. 28:01 We both believe that there's like an incredible intelligence to our body 28:05 that can actually do a lot of the counting 28:06 for us on that infinite complexity that we can't do for ourselves. 28:09 It's probably constantly saving our bacon. Right? 28:12 Like for our own minute of every hour of every day is my theory. 28:16 Yes. Yeah. 28:17 It's so it's like, I know you've said this many times, I keep saying this. 28:20 It's brilliant at keeping you alive. 28:22 Right? It's so brilliant. 28:24 The problem, of course, is it'll keep you alive when all the inputs are wrong. 28:28 And then that gets to be the entrained homeostatic pattern. 28:31 And now you've got to do a lot of work to get it to go back to the other one. 28:35 But because its job was to keep you alive and to keep you safe, right. 28:38 That's what it's supposed to do. 28:39 And it does it. 28:41 And it's amazing and I'm grateful for that. 28:43 But with these peptides, what I see is you're potentiated these improvements. 28:47 But if these improvements aren't going to actually be improvements 28:50 as far as the body is concerned, nothing's going to even happen from that. 28:53 Yeah, right. 28:53 You know, but if they could potentially improve 28:56 functionality, maybe this enzyme hasn't been robust. 29:00 And it really is important in the retina when it comes to intraocular eye pressure. 29:04 I'm taking a big leap forward on those mechanisms. 29:07 But let's just say it is. 29:09 And you know somebody with early glaucoma which threatens peptide. 29:12 Oh that's another of my favorites which has studies in early glaucoma. 29:16 Right. Really in humans. Yes. 29:18 That and macular degeneration. 29:19 And so this one, this particular enzyme is no longer being produced in a robust 29:25 way, in some way mechanistically ties into intraocular pressure. 29:29 Now this enzyme is being produced 29:32 those mechanisms mechanisms click into place and indirect pressure is stabilized. 29:36 Right. 29:36 But if in fact there is no issue with interactive pressure, 29:39 then nothing's going to happen to interrupt your pressure that yeah. 29:42 Now of course it's doing more than just. 29:44 And again I'm taking license with an enzyme and interactive pressure. 29:49 But I just know that is a studied endpoint for the retinal peptide 29:53 that has some favorable data to it. 29:55 So so does macular degeneration. 29:58 So then there are other 29:59 there are other aspects of that genetic expression 30:01 that tie into the health of the retina itself, separate from say interviewer 30:06 I pressure mechanisms. Right. Yeah. 30:08 So they're elegant and I and I take a great comfort 30:11 in their safety profile and that we're potentiate the body moving 30:16 in a direction that is, you know, is in the camp of robustness and resiliency. 30:22 But the body will only utilize that if that's what it needs to do. 30:27 Yeah. 30:28 Bringing it back to function with the retinal. 30:31 Do you stack it with others like the blood vessel. 30:33 Especially if you would think that's what would be critical. 30:36 Yeah. 30:37 So when when Doctor Lawrence was kind enough to send me Kevin's 30:40 little very dense book, there was a yeah, there was a whole chapter on retina 30:45 and there were some with the before and after pictures of the fundus 30:48 right of the retina itself showing these changes and working off of a recall from 30:53 I haven't read that book and, you know, a few years now, but in my recollection, 30:58 the retina was always with that core stack.
Thyroid, Retina, Brain, and Lung Applications 31:01 What vessel, of course, makes perfect sense. 31:03 But it's most retinal problems have a endothelial micro circulatory component. 31:07 But then circadian biology in the retina. 31:09 How intimate is that relationship. 31:11 And then pineal is how how intimate is 31:15 not only the thymus with the pineal gland. 31:18 Right. 31:18 Because those two actually there's some evidence 31:20 that the thymus influences pineal genetic expression. 31:23 And the pineal expression influences thymus, where 31:26 most of them are influencing expression only in their target tissue. 31:30 Those two appear to be talking to each other. 31:32 So it makes sense to me that if you're going to try and either 31:36 protect the retina or improve retinal function, somebody 31:39 who has diminished function, you want all those mechanisms working together. 31:43 Yeah. 31:43 Yeah, I actually think I read somewhere and you've been in the literature 31:47 a bit more recently than me. 31:49 I feel like I've read somewhere that the pineal bio regulator 31:52 actually has some impact on the optic nerve as well. 31:56 I'll have to look for that. Did you come? Yeah. 31:58 I didn't come across that, but it was either, 32:00 you know, it might have been pineal or it might have been the brain. 32:03 I bet it might have been the brain, because the research on that makes me, 32:07 I've been using it in people with potentially any sign 32:11 of a neurodegenerative disease post post-concussion traumatic brain injury. 32:16 But the the data around the brain. 32:20 But it's you're going to know this. 32:22 I'm going to look at it real quick 32:23 because I think this one is possibly, possibly underutilized. 32:26 I don't know what other doctors are we talking pineal on and or cortex in now. 32:30 Yeah. 32:31 But it's not it is the there's a couple of them. 32:34 There's a different one. 32:35 So the brain caught so there's cortex and then let's see 32:38 the strongest clinical literature is around cortex in right 32:42 which is not a single defined short peptide 32:44 but a polypeptide complex from cerebral cortex tissue. 32:48 That's different than what they call it cortex or something like that, which is. 32:54 Yeah, well into the synthetic 32:56 the data is much more robust for cortex and then quarter gen. 33:00 Yeah. Yeah. 33:02 Well it's you know, the nomenclature of these beautiful molecules 33:05 is enough to drive someone completely batty. 33:09 Yes. Yeah. 33:10 What of my giveaways for this summit is actually a table 33:15 demystifying names that will help people enormously. 33:19 Yes. Yeah. 33:20 I remember in Kevin spoke them you know, looking at it 33:23 was, you know, it would count as antidotes because it wasn't like a high number. 33:27 But looking at post traumatic brain injury, but also post-stroke 33:30 and saying they were favorable at least mechanisms. 33:34 But cortex was associated with better recovery 33:36 of motor and cognitive function and improved EEG patterns, 33:39 including increased alpha activity and reduced slow wave 33:42 sharp wave activity near the ischemia zone with no side effects. 33:46 And this was an early ischemic stroke. 33:50 Yeah, yeah, yeah. 33:51 So you could imagine 33:52 I mean, I definitely know people in this space who have their pre-mixed 33:56 kind of their pre-prepared stacks in the freezer with a big note on it. 34:01 You know, if I get a stroke, this is what you're doing. 34:04 Yeah. Early intervention. 34:06 Yeah, yeah, yeah. 34:08 Along with all the things. Right. The molecular hydrogen. 34:11 Yeah. 34:11 We're not we're not going to just put them on, you know, and then call it a day. 34:15 Right. 34:15 We're going to be supporting every other aspect of brain repair 34:18 I think in a kind of brain injury, you know, a person could go ketogenic. 34:22 But exogenous ketones is a very good intervention. 34:25 It's a lot faster for starters. Absolutely. 34:28 But the two that I I'm interested in all of them, 34:31 I think all these peptides like, you know, I'd like to use them all all the time. 34:35 But the two that from the standpoint of case study treatment, like, you know, 34:40 can we modify disease that have my highest level of interest outside of what we've 34:44 already talked about, are the core cortex in and the long bronchus? 34:49 Jen, I think there's a lot of potential there in earlier stages 34:53 of lung disease before it's become just fibrotic scar tissue to change. 34:57 Yeah epithelial expression and alone beautiful. 35:01 Well surprise, surprise sir. 35:03 We filled up over half an hour of content here. 35:06 What I'd like to do is invite you to share with people your coordinates, 35:10 where they can find out more about you and your work that you do, 35:14 so that if anybody needs more guests in their life, 35:17 which I can tell you, we all need more doctor guests in their life. 35:21 Sweet. 35:22 They know where to find you. 35:24 Yeah. Thank you. 35:24 Our clinic is called Authentic Health. 35:26 It's in the mountains of North Carolina. 35:28 We do work with people from around the country. 35:30 Depending on where they're located. 35:32 That's health, authentic health. 35:35 I do have a personal website. 35:39 But we're for the most part, 35:41 we're trying to migrate all that into our clinic umbrella. 35:43 But those would be the ways to find me and find information 35:46 on our clinic or blogs or anything, like all the podcasts 35:49 that I've done with Natalie that are so popular would be listed there. 35:52 We've got another one coming up in the fall sometimes. So yes. 35:55 Stay tuned. 35:56 All right. 35:56 Well, Doctor Vicary, 35:57 thank you so much, as always for your time and for being so generous 36:01 with your wisdom. 36:02 And we'll talk again soon. Thank you. 36:05 Yeah. Well, thank you for introduced me to by a regulatory peptides. 36:07 Natalie. My pleasure.
Comments